Catalent Pharma, a global provider of development sciences and manufacturing platforms for medicines and consumer health products, has announced its agreement to acquire Bettera Holdings for $1 billion. Bettera is a leading manufacturer in the rapidly growing gummy, soft chew, and lozenge segments of the nutritional supplements market. With this acquisition, Catalent aims to expand its global softgel and oral dose formulation and manufacturing business, offering unrivaled choice, formulation expertise, and high-quality manufacturing solutions.

Bettera brings expertise in developing consumer-preferred products for nutraceutical ingredients and operates four production facilities in the U. S. This acquisition will enhance Catalent's consumer health technology platform, providing a wider range of technologies, ready-to-market product libraries, and diverse packaging options.

It will also allow Catalent to leverage its network of manufacturing sites across North and South America, Europe, and Japan, expanding formulation development and supply solutions for the global consumer health and beauty markets. The acquisition is expected to close by the end of 2021